tbuckley/cabot-search huggingface dataset:
Journal of Gerontology, St. Louis
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Endocrine Society 67th Annual Meeting—Baltimore, Maryland, June 19–21, 1985
Journal: Endocrine Reviews (1985)

Journal Article The Endocrine Society 67th Annual Meeting—Baltimore, Maryland, June 19–21, 1985 Get access Endocrine Reviews, Volume 6, Issue 1, 1 January 1985, Page 104, https://doi.org/10.1210/edrv-6-1-104 Published: 01 January 1985
Pharmacology-Therapeutics
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oral Surgery
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New England Journal of Medicine, Boston
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
Authors: Kei Muro, Hiroyuki Uetake, Katsuya Tsuchihara, Kohei Shitara, Kentaro Yamazaki, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Kouji Iwasaki, Junpei Soeda, Masamitsu Hihara, Takeharu Yamanaka, Atsushi Ochiai, Takayuki Yoshino
Journal: Journal of Clinical Oncology (2016)

TPS3625 Background: Optimal combination of monoclonal antibody (anti-VEGF vs. anti-EGFR antibody) with standard chemotherapy as first-line treatment in patients (pts) with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer (mCRC) remains controversial. The FIRE-3 study demonstrated a significant improvement in overall survival (OS) with anti-EGFR over bevacizumab in pts with KRAS exon 2 wild-type mCRC, while the CALGB 80405 study did not. This study is designed to compare panitumumab with bevacizumab plus mFOLFOX6 in pts with RAS wild-type chemotherapy-naive mCRC. Methods: Eligible pts are aged 20-79 years and ECOG performance status 0-1 with histologically/cytologically confirmed RAS wild-type mCRC. A total of 800 pts will be randomly assigned in a 1:1 ratio to mFOLFOX6 plus panitumumab or bevacizumab and stratified by institution, age (20-64 vs. 65-79 years), and liver metastases (present vs. absent). Treatment regimens include oxaliplatin 85 mg/m2, concurrent with l-leucovorin 200 mg/m2, followed by 5-fluorouracil (5-FU) iv bolus 400 mg/m2 at day 1, followed by 46-hour 5-FU infusion 2400 mg/m2 and either panitumumab 6 mg/kg or bevacizumab 5 mg/kg at day 1 every two weeks. The primary endpoint is OS; the study was designed to detect the OS hazard ratio of 0.76, with a one-sided type I error of 0.025 and 80% power. An interim analysis is planned for the OS when approximately 70% of the targeted 570 events have occurred. A large-scale exploratory biomarker substudy to identify potential biomarker candidates using tumor tissue and circulating tumor DNA (ctDNA) is also underway (Study ID: NCT02394834). Tumor tissue samples will be collected before chemotherapy. Plasma samples will be obtained before and after chemotherapy. Paired pretreatment DNA from primary tissue and ctDNA will be analyzed using an NGS-based platform to evaluate potential biomarkers for each treatment arm. Pretreatment and post-treatment ctDNA will also be analyzed to investigate resistance mechanisms for each treatment. As of January 2016, 98 pts have been randomized. Results are expected in 2020. Clinical trial information: NCT02394795.
Preclinical assessment of the bioequivalence of branded and generic oxaliplatin and incidence of hypersensitivity reactions in patients with advanced colorectal cancer
Authors: M. Tampellini, A. La Salvia, C. Baratelli, F. Di Scipio, E. Pirro, M.P. Brizzi, C. Sonetto, M. Di Maio, G.N. Berta, G.V. Scagliotti
Journal: Annals of Oncology (2016)
JAMA Surgery
Journal: JAMA Surgery (2018)

Burnout is one of the major challenges facing physicians and is increasingly prevalent in the surgical community.Williford and colleagues analyzed the perceptions of burnout and depression among 147 surgical residents and faculty in North Carolina with validated survey metrics.Both cohorts underestimated the true prevalence of these conditions but identified the same barriers to seeking care. Invited Commentary 711 Continuing Medical Education jamanetwork.com/learning Resident Expectations of Training and Risk of Attrition 712General surgery resident expectations of training and their subsequent risk of attrition have not been evaluated.Abelson and colleagues performed a prospective cohort study of 828 residents over 9 years and found that interns with realistic expectations were less likely to drop out of training.
Efficacité et sécurité d’une préparation colique d’un litre de NER 1006 versus 2L de polyethylène glycol + acide ascorbique: un essai randomisé de phase 3
Journal: Endoscopy (2018)

Une préparation colique efficace est un prérequis indispensable à une détection de qualité. Après avoir montré que les PEG 2 L étaient équivalents aux PEG 4 L, on pouvait penser que l’histoire des PEG s’en tiendrait là.
Hematopoietic Stem Cells Develop in the Absence of Endothelial Cadherin 5 Expression
Authors: Heidi Anderson, Taylor Patch, Pavan Reddy, Elliott Hagedorn, Owen J. Tamplin, Daniel E. Bauer, Barry H. Paw, Dietmar Vestweber, Leonard I. Zon, Stuart H. Orkin, George Q. Daley, Dhvanit I. Shah
Journal: Blood (2015)
Error in Byline
Authors: Mehdi Bouslama, Leticia Rebello, Raul Nogueira, Raul Gomes Nogueira
Journal: JAMA Neurology (2017)

ues.By contrast, our patient cohort was exclusively composed of patients with high NIHSS scores.Moreover, our matching approach based on age, pretreatment glucose levels, and a computed tomography perfusion ischemic core resulted in very well-balanced groups.Specifically, the baseline NIHSS values (median [interquartile range], 19.5 [15.25-24] in the intervention arm; median [interquartile range], 18 [15][16][17][18][19][20][21][22][23] in the control group; both P = .22),as well as the total hypoperfused volumes (T max > 6 seconds; 205.4 mL ± 87.7 vs 210.8 mL ± 62.6, P = .77)were comparable between the groups.Similarly, stroke laterality was equivalent across the 2 groups with 57.1% of strokes affecting the left hemisphere in the intervention arm vs 53.6% among the control group (P = .99as assessed by the McNemar test for discordant pairs).It is also important to emphasize that endovascular therapy resulted not only in a favorable shift in 90-day outcomes, but also in a dramatic reduction in final infarct volumes (86.5 mL ± 76.9 mL vs 241.9 mL ± 120.3 mL, P < .001),highlighting not only the internal consistency but also the relative independence of the treatment effect from regional eloquence and laterality.As previously acknowledged, our study has the obvious limitations that are inherent to every retrospective analysis.However, to our knowledge, it represents the first matched case-control analysis exploring the potential benefit of endovascular treatment among a sizable patient population that has been historically assumed to invariably have a dismal prognosis.
Serum hyaluronate in the assessment of liver endothelial cell function after orthotopic liver transplantation in the rat
Authors: H Shimizu
Journal: Hepatology (1994)

This study was designed to evaluate the use of serum hyaluronate as a marker of liver endothelial cell function after liver transplantation. We performed orthotopic liver transplantation in both isogeneic and allogeneic rejector models. After transplantation, hepatocyte function was assessed on the basis of serum ALT and total bilirubin levels, and liver endothelial cell function was judged on the basis of serum hyaluronate levels. Significant increase of hyaluronate in the rejector model, compared with the isogeneic model, was seen before any significant results could be obtained from conventional liver function tests. The impaired metabolism of hyaluronate in the rejector model was observed after intravenous injection of trace amounts of radioactive material. Serial studies demonstrate that the endothelial cell is a more susceptible target for the immune response than the hepatocyte. Serum hyaluronate concentration may be a better indicator in the early assessment of graft function. We also examined serum hyaluronate levels to evaluate cold ischemia-reperfusion injury to the liver endothelial cells in the isogeneic model. At 2 hr after reperfusion, hyaluronate levels in the 6-hr cold ischemia (nonviable allograft) group were significantly higher than in the 1-hr and 3-hr cold ischemia (viable allograft) groups. However, there was little difference between the viable allograft groups. After an intravenous injection of 1 mg/kg hyaluronate, the hyaluronate elimination rate in the 3-hr group was distinctly slower than that in the 1-hr group. These data indicate that the hyaluronate elimination rate may be a more sensitive marker of liver endothelial cell function in viable liver after a short period of ischemia. (Hepatology 1994;20:1323–1329).
RESISTANCE OF THE THYROID TO STIMULATING SUBSTANCES
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"RULES AND REGULATIONS" UPHELD.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Health Assessment of Senior Officers
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Ethics
Authors: Edmund D. Pellegrino
Journal: JAMA (1986)

From the voluminous literature on the subject of biomedical ethics, three topics will be reviewed: artificial feeding, acquired immunodeficiency syndrome (AIDS), and the physician as "gatekeeper." Each exposes controversies and unsettled ethical issues of urgent interest to health professionals. Since the Quinlan case, discontinuance of certain life-support measures in permanently comatose patients has received legal and ethical sanction.<sup>1-3</sup>In the past year, intensive debate has centered on whether artificial nutrition and hydration are to be classified as medical treatments and also discontinued if futile or burdensome. Three court cases illustrate the controversial nature of the question and raise new ethical issues. In the Brophy case, the court refused permission to remove a gastrostomy tube on grounds that the patient was not terminal, the tube was not burdensome, and the intent to hasten death was inadmissible.<sup>4</sup>The opinion relied on the distinction, which many ethicists reject, between withholding and withdrawing
&lt;TITLE&gt;Driving Safely by Avoiding Alcohol&lt;/TITLE&gt;
Journal: JAMA (2000)

public service of JAMA and the AMA.The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis.For specific information concerning your personal medical condition, JAMA and the AMA suggest that you consult your physician.This page may be reproduced noncommercially by physicians and other health care professionals to share with patients.Any other reproduction is subject to AMA approval.
Modifiers of exposure-response estimates for lung cancer among miners exposed to radon progeny.
Authors: R W Hornung, J Deddens, R Roscoe
Journal: Environmental Health Perspectives (1995)

The association between lung cancer and exposure to radon decay products has been well established. Despite agreement on this point, there is still some degree of uncertainty regarding characteristics of the exposure-response relationship. The use of studies of underground miners to estimate lung cancer risks due to residential radon exposure depends upon a better understanding of factors potentially modifying the exposure-response relationship. Given the diversity in study populations regarding smoking status, mining conditions, risk analysis methodology, and referent populations, the risk estimates across studies are quite similar. However, several factors partially contributing to differences in risk estimates are modified by attained age, time since last exposure, exposure rate, and cigarette smoking patterns. There is growing agreement across studies that relative risk decreases with attained age and time since last exposure. Several studies have also found an inverse exposure-rate effect, i.e., low exposure rates for protracted duration of exposure are more hazardous than equivalent cumulative exposures received at higher rates for shorter periods of time. Additionally, the interaction between radon exposure and cigarette smoking appears to be intermediate between additive and multiplicative in a growing number of studies. Quantitative estimates of these modifying factors are given using a new analysis of data from the latest update of the Colorado Plateau uranium miners cohort.
Answering the Endocrine Test Questions
Authors: Charles W. Schmidt
Journal: Environmental Health Perspectives (1999)

Evidence suggesting that certain chemicals may bind to endogenous hormone receptors and disturb normal endocrine functioning, thereby increasing the risk of reproductive problems and cancer in humans, has led to international efforts to screen chemicals for endocrine activity and potential health effects. The U.S. Environmental Protection Agency (EPA) has recommended that some 87,000 commercial chemicals for which there currently are inadequate toxicity data be evaluated. In December 1998, the EPA's Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC) recommended the use of a tiered system of screening and testing assays to sequentially eliminate chemicals for which further testing is deemed unnecessary. The first step toward implementing such a system-validation of the tests to be used-is presenting some challenges, however, with stakeholders disagreeing over which tests to validate, how extensively to validate them, and how much it will cost.
Epidemiologic Approaches to Persons with Exposures to Waste Chemicals
Authors: Philip J. Landrigan
Journal: Environmental Health Perspectives (1983)

Evaluation of disease in populations exposed to hazardous waste dumps requires: documentation of the chemicals in a dump; assessment of the materials released from the dump into environmental media; tracing of the probable routes of human exposure (groundwater, air, direct contact, or occupational); development, when possible, of individual exposure estimates and/or direct biological assessment of absorption; precise definition of the subpopulations at highest risk of exposure; and the employment of specific and sensitive health outcome indicators. Demonstration of dose-response relationships between chemical exposure and disease provides the most compelling evidence for a chemical etiology of illness in exposed populations. Interpretation of apparently negative data must be cautious, given the small size of most high-risk populations and the usual brevity of exposures.
Intercapillary Glomerulosclerosis
Authors: Paul Kimmelstiel, William B. Porter
Journal: New England Journal of Medicine (1948)

IN 1936 a small series of cases was reported by Kimmelstiel and Wilson1 showing a conspicuous correlation between a syndrome of diabetes, nephrotic edema, gross albuminuria and hypertension and a peculiar type of intercapillary sclerosis of glomeruli. The nature of this investigation, taking its origin from systematic analysis of a large volume of autopsy material, precluded a specific detailed study of clinical features. The relatively scant clinical information was merely sufficient to emphasize the significance of the histologic findings. A large number of similar cases have been reported during the last twelve years, and with them a wealth of clinical . . .